{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:10:01Z","timestamp":1791112201245,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1124\/jpet.107.126219","type":"journal-article","created":{"date-parts":[[2007,7,28]],"date-time":"2007-07-28T01:10:36Z","timestamp":1185585036000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"323","author":[{"given":"Daniel B.","family":"Putterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Munhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Kozell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.107.126219_bib1","doi-asserted-by":"crossref","unstructured":"Andersson M, Hilbertson A, and Cenci MA (1999) Striatal fos B expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 6: 461\u2013474.","DOI":"10.1006\/nbdi.1999.0259"},{"key":"10.1124\/jpet.107.126219_bib2","doi-asserted-by":"crossref","unstructured":"Aubert I, Guigoni C, H\u00e5kansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57: 17\u201326.","DOI":"10.1002\/ana.20296"},{"key":"10.1124\/jpet.107.126219_bib3","doi-asserted-by":"crossref","unstructured":"Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, and Gross CE (2001) Relationship between the appearance of symptoms and the level of nitrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease. J Neurosci 21: 6853\u20136861.","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001"},{"key":"10.1124\/jpet.107.126219_bib4","doi-asserted-by":"crossref","unstructured":"Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, and Walker PD (2006) MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23: 2669\u20132676.","DOI":"10.1111\/j.1460-9568.2006.04790.x"},{"key":"10.1124\/jpet.107.126219_bib5","doi-asserted-by":"crossref","unstructured":"Boulet S, Lacombe E, Carcenac C, Feuerstein C, Sgambato-Faure V, Poupard A, and Savasta M (2006) Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J Neurosci 26: 10768\u201310776.","DOI":"10.1523\/JNEUROSCI.3065-06.2006"},{"key":"10.1124\/jpet.107.126219_bib6","doi-asserted-by":"crossref","unstructured":"Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, and Cenci MA (2006) Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96: 1718\u20131727.","DOI":"10.1111\/j.1471-4159.2006.03696.x"},{"key":"10.1124\/jpet.107.126219_bib7","doi-asserted-by":"crossref","unstructured":"Cenci MA, Lee CS, and Bj\u00f6rklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10: 2694\u20132706.","DOI":"10.1046\/j.1460-9568.1998.00285.x"},{"key":"10.1124\/jpet.107.126219_bib8","doi-asserted-by":"crossref","unstructured":"Chang J-W, Wachtel SR, Young D, and Kang U-J (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson\u2019s disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88: 617\u2013628.","DOI":"10.1016\/S0306-4522(98)00217-6"},{"key":"10.1124\/jpet.107.126219_bib9","doi-asserted-by":"crossref","unstructured":"Corvol JC, Muriel M-P, Valjent E, F\u00e9ger J, Hanoun N, Girault J, Hirsch EC, and Herv\u00e9 D (2004) Persistent increase in olfactory type G-protein \u03b1 subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24: 7007\u20137014.","DOI":"10.1523\/JNEUROSCI.0676-04.2004"},{"key":"10.1124\/jpet.107.126219_bib10","doi-asserted-by":"crossref","unstructured":"de la Fuente-Fern\u00e1ndez R, Sossi V, Huang Z, Furtado S, Lu J-Q, Calne DB, Ruth TJ, and Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain 127: 2747\u20132754.","DOI":"10.1093\/brain\/awh290"},{"key":"10.1124\/jpet.107.126219_bib11","doi-asserted-by":"crossref","unstructured":"Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, and Calabresi P (2006) A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J Neurosci 26: 2914\u20132922.","DOI":"10.1523\/JNEUROSCI.5326-05.2006"},{"key":"10.1124\/jpet.107.126219_bib12","doi-asserted-by":"crossref","unstructured":"Grandas F, Galiano ML, and Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson\u2019s disease. J Neurol 246: 1127\u20131133.","DOI":"10.1007\/s004150050530"},{"key":"10.1124\/jpet.107.126219_bib13","doi-asserted-by":"crossref","unstructured":"Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, and Standaert DG (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Neuropharmacology 48: 503\u2013516.","DOI":"10.1016\/j.neuropharm.2004.11.008"},{"key":"10.1124\/jpet.107.126219_bib14","doi-asserted-by":"crossref","unstructured":"Hefti F, Melamed E, Sahakian BJ, and Wurtman RJ (1980) Circling behavior in rats with partial, unilateral nigro-striatal lesions: effects of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav 12: 185\u2013188.","DOI":"10.1016\/0091-3057(80)90353-6"},{"key":"10.1124\/jpet.107.126219_bib15","doi-asserted-by":"crossref","unstructured":"Henry B, Crossman AR, and Brotchie JM (1998) Characterization of enhanced behavioral responses to l-dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. Exp Neurol 151: 334\u2013342.","DOI":"10.1006\/exnr.1998.6819"},{"key":"10.1124\/jpet.107.126219_bib16","doi-asserted-by":"crossref","unstructured":"Hurtig HI (1997) Problems with current pharmacologic treatment of Parkinson\u2019s disease. Exp Neurol 144: 10\u201316.","DOI":"10.1006\/exnr.1996.6380"},{"key":"10.1124\/jpet.107.126219_bib17","doi-asserted-by":"crossref","unstructured":"Kish SJ, Shannak K, and Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease. N Engl J Med 318: 876\u2013880.","DOI":"10.1056\/NEJM198804073181402"},{"key":"10.1124\/jpet.107.126219_bib18","doi-asserted-by":"crossref","unstructured":"Konitsiotis S and Tsironis C (2006) Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon? Behav Brain Res 170: 337\u2013341.","DOI":"10.1016\/j.bbr.2006.02.030"},{"key":"10.1124\/jpet.107.126219_bib19","doi-asserted-by":"crossref","unstructured":"Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, Axelrod JD, Cheyette BN, Simon MI, Lester HA, et al. (2005) D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 25: 2157\u20132165.","DOI":"10.1523\/JNEUROSCI.2840-04.2005"},{"key":"10.1124\/jpet.107.126219_bib20","doi-asserted-by":"crossref","unstructured":"Lee CS, Cenci MA, Schulzer M, and Bj\u00f6rklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Brain 123: 1365\u20131379.","DOI":"10.1093\/brain\/123.7.1365"},{"key":"10.1124\/jpet.107.126219_bib21","doi-asserted-by":"crossref","unstructured":"Lindgren HS, Rylander D, Ohlin KE, Lundblad M, and Cenci MA (2007) The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration. Behav Brain Res 177: 150\u2013159.","DOI":"10.1016\/j.bbr.2006.09.019"},{"key":"10.1124\/jpet.107.126219_bib22","doi-asserted-by":"crossref","unstructured":"Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, and Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease. Eur J Neurosci 15: 120\u2013132.","DOI":"10.1046\/j.0953-816x.2001.01843.x"},{"key":"10.1124\/jpet.107.126219_bib23","doi-asserted-by":"crossref","unstructured":"Meshul CK and Allen C (2000) Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion. Synapse 36: 129\u2013142.","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<129::AID-SYN6>3.0.CO;2-4"},{"key":"10.1124\/jpet.107.126219_bib24","doi-asserted-by":"crossref","unstructured":"Morelli M, Fenu S, Garau L, and Di Chiara G (1989) Time and dose dependence of the \u201cpriming\u201d of the expression of dopamine receptor supersensitivity. Eur J Pharmacol 162: 329\u2013335.","DOI":"10.1016\/0014-2999(89)90296-3"},{"key":"10.1124\/jpet.107.126219_bib25","doi-asserted-by":"crossref","unstructured":"Mura A, Mintz M, and Feldon J (2002) Behavioral and anatomical effects of long-term l-dihydroxyphenylalanine (l-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 177: 252\u2013264.","DOI":"10.1006\/exnr.2002.7976"},{"key":"10.1124\/jpet.107.126219_bib26","unstructured":"Nutt JG (1992) Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson\u2019s disease, in Drug-Induced Movement Disorders (Lang AE and Weiner WJ eds) pp 281\u2013314, Futura Publishing Co., Inc., Mt. Kisco, NY."},{"key":"10.1124\/jpet.107.126219_bib27","doi-asserted-by":"crossref","unstructured":"Nutt JG, Woodward WR, Carter JH, and Gancher ST (1992) Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 49: 1123\u20131130.","DOI":"10.1001\/archneur.1992.00530350037016"},{"key":"10.1124\/jpet.107.126219_bib28","doi-asserted-by":"crossref","unstructured":"Oh JD, Russell D, Vaughan CL, and Chase TN (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration. Brain Res 813: 150\u2013159.","DOI":"10.1016\/S0006-8993(98)01049-X"},{"key":"10.1124\/jpet.107.126219_bib29","doi-asserted-by":"crossref","unstructured":"Paill\u00e9 V, Brachet P, and Damier P (2004) Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson\u2019s disease. NeuroReport 15: 561\u2013564.","DOI":"10.1097\/00001756-200403010-00035"},{"key":"10.1124\/jpet.107.126219_bib30","doi-asserted-by":"crossref","unstructured":"Papa SM, Engber TM, Kask AM, and Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662: 69\u201374.","DOI":"10.1016\/0006-8993(94)90796-X"},{"key":"10.1124\/jpet.107.126219_bib31","unstructured":"Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA."},{"key":"10.1124\/jpet.107.126219_bib32","doi-asserted-by":"crossref","unstructured":"Picconi B, Centonze D, Hak\u00e5nsson K, Bernardi G, Greengard P, Fisone G, Cenci MA, and Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nature Neurosci 6: 501\u2013506.","DOI":"10.1038\/nn1040"},{"key":"10.1124\/jpet.107.126219_bib33","doi-asserted-by":"crossref","unstructured":"Schrag A and Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain 123: 2297\u20132305.","DOI":"10.1093\/brain\/123.11.2297"},{"key":"10.1124\/jpet.107.126219_bib34","doi-asserted-by":"crossref","unstructured":"Soghomonian J-J (2006) l-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. Eur J Neurosci 23: 2395\u20132403.","DOI":"10.1111\/j.1460-9568.2006.04758.x"},{"key":"10.1124\/jpet.107.126219_bib35","doi-asserted-by":"crossref","unstructured":"Taylor JL, Bishop C, Ullrich T, Rice KC, and Walker PD (2006) Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 50: 761\u2013768.","DOI":"10.1016\/j.neuropharm.2005.12.004"},{"key":"10.1124\/jpet.107.126219_bib36","doi-asserted-by":"crossref","unstructured":"Taylor JL, Bishop C, and Walker PD (2005) Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81: 887\u2013893.","DOI":"10.1016\/j.pbb.2005.06.013"},{"key":"10.1124\/jpet.107.126219_bib37","doi-asserted-by":"crossref","unstructured":"Ungerstedt U (1971) Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol Scand Suppl 367: 49\u201368.","DOI":"10.1111\/j.1365-201X.1971.tb10999.x"},{"key":"10.1124\/jpet.107.126219_bib38","doi-asserted-by":"crossref","unstructured":"Ungerstedt U and Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485\u2013493.","DOI":"10.1016\/0006-8993(70)90187-3"},{"key":"10.1124\/jpet.107.126219_bib39","doi-asserted-by":"crossref","unstructured":"Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, and Cenci MA (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia. J Neurosci 26: 9448\u20139461.","DOI":"10.1523\/JNEUROSCI.0944-06.2006"},{"key":"10.1124\/jpet.107.126219_bib40","doi-asserted-by":"crossref","unstructured":"Winkler C, Kirik D, Bj\u00f6rklund A, and Cenci MA (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10: 165\u2013186.","DOI":"10.1006\/nbdi.2002.0499"},{"key":"10.1124\/jpet.107.126219_bib41","doi-asserted-by":"crossref","unstructured":"Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, et al. (2005) Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease. Arch Neurol 62: 601\u2013605.","DOI":"10.1001\/archneur.62.4.601"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524341084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524341084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.107.126219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:25:14Z","timestamp":1740003914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524341084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0022356524341084"],"URL":"https:\/\/doi.org\/10.1124\/jpet.107.126219","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.107.126219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}